US Patent

US12109185 — Levodopa dosing regimen

Method of Use · Assigned to Amneal Pharmaceuticals LLC · Expires 2041-12-21 · 16y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects oral dosing regimens of controlled release levodopa compositions for treating Parkinson's disease and related conditions.

USPTO Abstract

The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and the dosing regimens provide an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1649 — Sinemet Cr
U-1649 — Sinemet Cr
U-1649 — Sinemet Cr
U-1649 — Sinemet Cr

Patent Metadata

Patent number
US12109185
Jurisdiction
US
Classification
Method of Use
Expires
2041-12-21
Drug substance claim
No
Drug product claim
No
Assignee
Amneal Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.